comparemela.com

Latest Breaking News On - Zevra therapeutics inc - Page 14 : comparemela.com

The Hidden Effects of Universal Proxy Cards

The introduction of universal proxy cards (“UPC”) for U.S. companies in September 2022 was intended to make it cheaper and more efficient for…

Danielj manglessZevra therapeutics incInstitutional shareholder servicesApartment investment management coAmarin corpWhat reallyGlass lewisLevel similarBelow priorApartment investmentSarissa capital managementZevra therapeuticsNew directors thanAw firmsAw updatesEgal updates

KP1077 for IH and Narcolepsy a Priority for Zevra

Zevra Therapeutics named KP1077, its investigational drug in development for idiopathic hypersomnia and narcolepsy, as a pivotal focus area.

Neilf mcfarlaneZevra therapeutics incInvestigational new drug

Zevra Therapeutics, Inc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023

Zevra Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 2.9 million compared to USD.

Zevra therapeutics incZevra therapeutics

Zevra Therapeutics: Q3 Earnings Snapshot

Zevra Therapeutics: Q3 Earnings Snapshot
qz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from qz.com Daily Mail and Mail on Sunday newspapers.

United statesZacks investment researchZevra therapeutics incZevra therapeuticsAutomated insightsZacks investment

Zevra Therapeutics Inc (ZVRA) Reports Q3 2023 Financial Results

Net Revenue of $2.9M and Cash Runway into 2026

Neilf mcfarlaneZevra therapeutics incAcer therapeuticsChief executive officerAcer therapeuticsCash equivalentsCash investmentsNet revenueRimoclomol nda

vimarsana © 2020. All Rights Reserved.